(LYB) LyondellBasell Industries - Overview
Stock: Olefins, Polyolefins, Polyethylene, Polypropylene, Catalysts
Dividends
| Dividend Yield | 9.53% |
| Yield on Cost 5y | 8.02% |
| Yield CAGR 5y | 5.26% |
| Payout Consistency | 92.3% |
| Payout Ratio | 2.2% |
| Risk 5d forecast | |
|---|---|
| Volatility | 42.8% |
| Relative Tail Risk | -4.86% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.42 |
| Alpha | -40.05 |
| Character TTM | |
|---|---|
| Beta | 1.262 |
| Beta Downside | 1.625 |
| Drawdowns 3y | |
|---|---|
| Max DD | 55.35% |
| CAGR/Max DD | -0.22 |
Description: LYB LyondellBasell Industries January 02, 2026
LyondellBasell Industries N.V. (NYSE: LYB) is a global chemical producer headquartered in Houston, Texas, with operations spanning the United States, Europe, Asia and Latin America.
The firm is organized into six operating segments: Olefins & Polyolefins (Americas, Europe/Asia/International), Intermediates & Derivatives, Advanced Polymer Solutions, Refining, and Technology licensing.
Its product slate includes core olefins (ethylene, propylene, butadiene), polyolefins (PE, PP), specialty polymers (catalloy, polybutene-1), propylene-oxide derivatives, and refined fuels, plus a suite of compounded plastics, masterbatches, and engineered composites for packaging, automotive, and coatings markets.
Key data points: FY 2023 adjusted EBITDA was roughly $5.5 billion with an EBITDA margin near 14 %; net debt stood at about $13 billion, yielding a net-debt/EBITDA ratio of ~2.4×. The company’s polyolefin capacity exceeds 8.5 million t/yr, making it one of the world’s largest producers, and its earnings are highly sensitive to natural-gas feedstock prices and the ethylene-propene spread, both of which are driven by macro-level demand in construction, packaging and automotive sectors.
For a deeper, data-driven dive into LYB’s valuation metrics, the ValueRay platform offers a transparent, model-backed view worth checking out.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: -603.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 1.17m > 0.02 and ΔFCF/TA 117.1m > 1.0 |
| NWC/Revenue: -0.00% < 20% (prev 15.11%; Δ -15.11% < -1%) |
| CFO/TA 4.24m > 3% & CFO 2.67b > Net Income -603.0m |
| Net Debt (-2262 ) to EBITDA (840.0m): -0.00 < 3 |
| Current Ratio: 0.74 > 1.5 & < 3 |
| Outstanding Shares: last quarter (325.0) vs 12m ago -100.00% < -2% |
| Gross Margin: 9.78% > 18% (prev 0.12%; Δ 965.5% > 0.5%) |
| Asset Turnover: 129.0% > 50% (prev 103.0%; Δ 26.08% > 0%) |
| Interest Coverage Ratio: -0.41 > 6 (EBITDA TTM 840.0m / Interest Expense TTM 400.0m) |
Altman Z'' 10.00
| A: -0.35 (Total Current Assets 630.0 - Total Current Liabilities 852.0) / Total Assets 630.0 |
| B: 14.8m (Retained Earnings 9.32b / Total Assets 630.0) |
| C: -0.01 (EBIT TTM -165.0m / Avg Total Assets 17.87b) |
| D: 0.34 (Book Value of Equity 7.81b / Total Liabilities 23.16b) |
| Altman-Z'' Score: 48.3m = AAA |
Beneish M -4.00
| DSRI: 1.60 (Receivables 3.55b/3.55b, Revenue 23.06b/36.80b) |
| GMI: 1.26 (GM 9.78% / 12.31%) |
| AQI: -135.0m (AQ_t -26.2m / AQ_t-1 0.19) |
| SGI: 0.63 (Revenue 23.06b / 36.80b) |
| TATA: -5.20m (NI -603.0m - CFO 2.67b) / TA 630.0) |
| Beneish M-Score: -85.4m (Cap -4..+1) = AAA |
What is the price of LYB shares?
Over the past week, the price has changed by +12.45%, over one month by +19.26%, over three months by +33.75% and over the past year by -22.15%.
Is LYB a buy, sell or hold?
- StrongBuy: 5
- Buy: 1
- Hold: 13
- Sell: 1
- StrongSell: 2
What are the forecasts/targets for the LYB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 49.5 | -10.1% |
| Analysts Target Price | 49.5 | -10.1% |
| ValueRay Target Price | 63.3 | 14.8% |
LYB Fundamental Data Overview January 31, 2026
P/S = 0.4256
P/B = 1.5169
P/EG = 1.0419
Revenue TTM = 23.06b USD
EBIT TTM = -165.0m USD
EBITDA TTM = 840.0m USD
Long Term Debt = 10.53b USD (from longTermDebt, last fiscal year)
Short Term Debt = 972.0m USD (from shortTermDebt, last fiscal year)
Debt = 12.92b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -2262 USD (from netDebt column, last quarter)
Enterprise Value = 29.00b USD (16.08b + Debt 12.92b - CCE 2262 )
Interest Coverage Ratio = -0.41 (Ebit TTM -165.0m / Interest Expense TTM 400.0m)
EV/FCF = 39.30x (Enterprise Value 29.00b / FCF TTM 738.0m)
FCF Yield = 2.54% (FCF TTM 738.0m / Enterprise Value 29.00b)
FCF Margin = 3.20% (FCF TTM 738.0m / Revenue TTM 23.06b)
Net Margin = -2.61% (Net Income TTM -603.0m / Revenue TTM 23.06b)
Gross Margin = 9.78% ((Revenue TTM 23.06b - Cost of Revenue TTM 20.81b) / Revenue TTM)
Gross Margin QoQ = none% (prev 11.73%)
Tobins Q-Ratio = 46.0m (set to none) (Enterprise Value 29.00b / Total Assets 630.0)
Interest Expense / Debt = 1.01% (Interest Expense 130.0m / Debt 12.92b)
Taxrate = 14.97% (240.0m / 1.60b)
NOPAT = -140.3m (EBIT -165.0m * (1 - 14.97%)) [loss with tax shield]
Current Ratio = 0.74 (Total Current Assets 630.0 / Total Current Liabilities 852.0)
Debt / Equity = 1.04 (Debt 12.92b / totalStockholderEquity, last fiscal year 12.46b)
Debt / EBITDA = -0.00 (Net Debt -2262 / EBITDA 840.0m)
Debt / FCF = -0.00 (Net Debt -2262 / FCF TTM 738.0m)
Total Stockholder Equity = 11.79b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.37% (Net Income -603.0m / Total Assets 630.0)
RoE = -5.11% (Net Income TTM -603.0m / Total Stockholder Equity 11.79b)
RoCE = -0.74% (EBIT -165.0m / Capital Employed (Equity 11.79b + L.T.Debt 10.53b))
RoIC = -0.60% (negative operating profit) (NOPAT -140.3m / Invested Capital 23.21b)
WACC = 6.24% (E(16.08b)/V(29.00b) * Re(10.57%) + D(12.92b)/V(29.00b) * Rd(1.01%) * (1-Tc(0.15)))
Discount Rate = 10.57% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -99.90%
[DCF Debug] Terminal Value 78.96% ; FCFF base≈1.08b ; Y1≈707.9m ; Y5≈323.0m
Fair Price DCF = 28.92 (EV 9.31b - Net Debt -2262 = Equity 9.31b / Shares 321.9m; r=6.24% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -83.03 | EPS CAGR: -58.05% | SUE: -3.91 | # QB: 0
Revenue Correlation: -88.45 | Revenue CAGR: -14.11% | SUE: 0.41 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.58 | Chg30d=-0.096 | Revisions Net=-5 | Analysts=9
EPS current Year (2026-12-31): EPS=3.33 | Chg30d=-0.187 | Revisions Net=-7 | Growth EPS=+96.0% | Growth Revenue=-2.9%
EPS next Year (2027-12-31): EPS=4.58 | Chg30d=-0.328 | Revisions Net=-3 | Growth EPS=+37.4% | Growth Revenue=-0.3%